Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If there are decent European revenues for Vascepa now available to Amarin, today would be the time for Amarin to release those figures publicly.
Nelson Peltz announced today that he will end his proxy fight with Disney...immediately after the announcement, Disney stock fell substantially.....This might be an indication of what will happen if Denner loses his proxy fight with Amarin.
onecard...She was probably referring to the FDC with a statin...but they have already announced it is for Europe, not for the U.S....for the U.S., it would take an investment in cash, which Amarin presently does not have enough of.
One....If Denner loses this proxy fight, he, with help from other hedge funds, could conceivably buy enough Amarin shares at these low prices to take the company private...with the goal of selling Amarin for a large gain along the road....If Denner wins, that wouldn't be necessary and we could all participate in this gain.
JRoon...QUOTE... the one big add was SCP Investments, who added 2,250,000 shares in Q4 and now hold 6.5M"
SCP is a boutiqe private equity firm INVESTING IN EUROPE...Hope they were not recruited by Amarin to side with them against Denner in order to continue to GIA in Europe.
JROON...I totally understand why KM would want to maintain his position as CEO...He would be a fool if he didn't want to...Our situation as shareholders is very different.
Festering...QUOTE..."Failing to support Marjac in the appeals against the generics is enough reason to vote the blue card."
I believe that Ekman was instrumental in recruiting Olsen...Olsen was, however, not to blame for Ekman,'s error...but I am still voting blue, not because of any personal animosity to Olsen, but because I believe that Denner and his group are the better ones to handle Amarin at this juncture.
Mr Stock...I would rather leave those decisions for Denner to make.
ggwpg... Denner's strategy is to prepare Amarin for a sale...Olsen's strategy is to GIA...The two plans are not mutually compatible.
I have had Amarin as my major investment for 12 years..through good times and bad...and now I believe it is time to sell the company.
ifso...If what you say were true, all Denner would need is just one of his associates on the board to keep him informed....but he wants PWO gone so he can do a better job of selling the company.
I just called Fidelity...The rep put me on hold for a few minutes while he contacted the departments involved in proxies...He came back and said that Fidelity had no information at this time on the Amarin vs. Sarissa situation...but that I would eventually have a choice as to whether to vote on line or by mail.
Downtown...Its nice that since Denner joined the fray. Amarin has, for the first time after many years of virtually ignoring shareholders, begun to take shareholders seriously.
Amarin may be offering misleading statistics...QUOTE...The median total shareholder return (“TSR”) at companies during the tenure of Sarissa-nominated directors is NEGATIVE 24%."
The more meaningful statistic would be...What was the price of the company when Sarissa initiated a proxy fight as opposed to the eventual sale price for the company...
Amarin stock price was hovering at close to a dollar a share this past summer...it is now is getting nearly double that...I fear that if Denner loses this proxy fight, the stock price will head down again....
Even Amarin is now hinting that they would be open to a sale of the company at the right price...Denner has the greater experience to effect such a sale.
I have all my Amarin stock held by Fidelity....I copied this quote from their website at 8 A.M.
QUOTE..."There are no open proxy campaigns available at this time. You can expect to be notified prior to a company meeting."
My understanding is that votes must be received in roughly 3 weeks from now in order to be counted...Amarin does not seem to be concerned about this short time frame...I hope Sarissa will comment on this.
It appears as though most retail investors are voting for Sarissa...Amarin is definitely aware of this....Amarin management might be more concerned that institutions get their vote in correctly, than they are concerned that retail voters get their vote in correctly....
Having said this, it seems that the voting rules are confusing to many retail investors...Tutes have large staffs and will definitely be able to figure out the vague rules better than would the retails...therefore the vague voting rules might tend to cause more retail voters to cast their vote incorrectly than would be the case with tutes...thus favoring the tutes.
In a close election, this factor, along with the short time frame being given to get your vote in...could make a critical difference in the results.
Amarin's main problem in the U.S. is EXCLUSIVITY LOSS for Vascepa...The best way to deal with this is to regain U.S. patent protection by marketing patented MND-2119 products...
Amarin's main problem in Europe is PRICE PUSHBACK on Vaskepa...The best way to deal with this is to regain markets by charging national health care systems for licenses in return for charging less for Vaskepa.
The end goal should be to make EPA products available globally for all adults.
The Amarin ship is being buffeted by waves...It takes a strong and experienced captain to get it back on course and to reach its destination...I will vote for Denner and his entire slate to get the job done.
Marjac...The proxy vote needing to be held so quickly seems unreasonable to me.... It seems reasonable that there should be some negotiation between Amarin and Sarissa on the time for the proxy to be voted upon.
It could even be that more negotiation might result in a compromise between the two sides.
Until now Denner seems to feel that Amarin has not been willing to negotiate in good faith.
Denner's proposal for countries with public health care systems was particularly interesting IMO.
QUOTE...(to various countries) "For an annual licensing fee, at a fraction of what Vascepa will save you in CVD cost, we will supply Vaskepa to your country."
I assume Amarin will profit from the licensing fee...Then Amarin can make individual prescriptions of Vaskepa very inexpensive...Then each country can decide for themselves how available they want Vaskepa to be for their patient population.
Amarin management seems to dislike Dennner, but the market seems to like him.
It is apparent that there is a significant difference in approaches between Denner and Olsen...
QUOTE.." Chairman Wold-Olsen astonishingly shared his view that only a shareholder who owned >20% of a company potentially should be offered ONE board seat. It is astounding that Per and the Amarin board are adamant to keep Sarissa principals and other shareholders out of the boardroom."
If this were the policy, then apparently NO shareholder would ever be able to attain a board seat.
Released at 4:09 p.m. today in business wire...
"https://www.businesswire.com/news/home/20230201005965/en/Sarissa-Capital-Urges-Amarin-Shareholders-to-Vote-the-Blue-Card-by-February-22-to-Fix-Amarin-for-the-Benefit-of-Shareholders
I called D.F. King and spoke to a woman, who told me that it was "only preliminary"
Capt...Thanks for the example...Vascepa deserves to be in the pantheon of world class drugs like statins and penicillins...but it needs new management to get it there.
One...When Amarin lost the U.S. market for their only product, their large overhead became unsustainable.
Europe is beset by problems and for Amarin to proceed without the U.S. market is NOT sustainable ...Amarin MUST get back the U.S. market and the best way to do this is with MND-2119 as a solo drug or as a statin-EPA FDC
Amarin has not pursued this avenue because they don't have the cash...ergo they must be sold.
Megc...QUOTE..."Mr. Wold-Olsen conveyed a message to Sarissa through counsel expressing a willingness to interview two of Sarissa’s candidates as part of the Board’s ongoing refreshment process"....I agree that this would be a step in the right direction.
Losing the patent case in the ninth circuit was first nail in the coffin...Losing the appeal was the second nail in the coffin...Losing reimbursement in Germany was the third nail in the coffin...Denner losing the proxy fight to PWO would be the fourth nail in the coffin....How many nails does it take for a coffin to get buried?
Amarin needs to wake up from its coffin and be transformed...PWO is the undertaker...Denner is the Doctor.
CBB...I believe that PWO is calling the shots, not KM...PWO seems unconcerned about the present trajectory of the company...This is why Denner is asking for the resignation of PWO and is seeking new board membership...I can not understand why anyone possessing a serious investment in Amarin would want Amarin to continue on its present course.
Amarin can have successful future, but not with the direction in which current management is proceeding.
The eventual solution to Amarin's problems is to regain the U.S. market for Vascepa...The settlement of the Healthnet case apparently is not going to do it....The patented gel capsule is not going to do it...An AG is apparently not going to do it...This leaves an FTC, preferably with MND-2119(with a re-instatement of reps and advertising) as the probable solution to Amarn's problem.
To undertake this strategy Amarin needs a well funded initiative by a cash rich BP.
Perhaps Denner could address the potential for MND-2119 in a combo with a statin...as a mechanism for re-establishing the U.S market for Amarin's EPA products....as one of his first directives after he takes over.
The current management of Amarin has apparently decided to pass on this opportunity.
conc...I hope that the PA's for gV show that the Rx,s are intended for the treatment of CVD...Then Amarin can pursue BCBS for infringement in the same fashion that they pursued Healthnet.
The main value of the NZ approval of Vaskepa is that it confirms what other government health administrators have already decided...i.e. that Vaskepa is valuable at reducing CVD and thereby saving health costs...not to mention lessening the toll of human suffering.
TTE...JT had a plan to ride the waves on Vascepa and eventually parlay Amarin into a BP...Judge Du put a stop to all that and now Amarin is just floundering with a GIA strategy...We need Denner to install a new sensible plan for Vascepa's future.
Capt...The Amarin-HLS deal has up front milestone payments to Amarin...I believe Amarin will have to pay Mochida double digit royalties but NO milestone payments...
QUOTE..."Under the Amarin-HLS agreement, HLS will be responsible for regulatory and commercialization activities and associated costs. Amarin is responsible for providing assistance towards local filings, supplying finished product, maintaining intellectual property and continuing the development and funding of REDUCE-IT. Terms of the agreement include up-front and milestone payments to Amarin of up to US$65.0 million. These payments include a non-refundable upfront payment of US$5.0 million, as well as development, regulatory and sale-based milestones totaling up to an additional US$60.0 million. The agreement also provides for HLS to pay Amarin tiered double digit royalties on net sales of Vascepa in Canada."
Since Vascepa is apparently profitable to HLS, even after shelling out milestone payments as well as royalties to Amarin...perhaps MND-2119 could be profitable to Amarin, either as a solo drug,or even better, as a combo drug with a statin...ESPECIALLY IF AMARIN COULD OBTAIN PATENT EXCLUSIVITY FOR MND-2119 IN THE U.S.
Nuke...A potential advantage of MND-2119(as opposed to Vascepa) is that a combo drug, using a statin plus MND-2119, might need be used only twice a day...or even only once a day....since the EPA in MND-2119 would be more easily absorbed by the patient's body, therefore allowing for a lower dose of the EPA in the gelatin capsule to produce the same effect...Using less EPA might even make the product cheaper to manufacture than Vascepa.
An as yet to be answered is whether Amarin would have to pay royalties to Mochida for the use of their product...in addition to the $2 million they paid up front to Mochida upon signing their collaboration agreement.
Capt...Since Amarin already has a patent for MND-2119 in the U.S., it seems reasonable for Amarin to initiate the process to obtain FDA approval in the U.S. ASAP....I'm surprised that Amarin has not already begun this process.
Now that Amarin has a patent granted for a statin-Vascepa drug combo...I would also like to know....
1. Has Amarin applied for an FDA approval for the combo drug?...
2. Will the combo drug be in the form of be a blister pack or a statin to be coated on to a Vascepa capsule?
3. What will be the dosages of the statin to be used in the combo drug?
4. Which statin will be used in the combo?
5. Does Amarin plan to seek approval from the U.S. FDA to use MND-2119 either alone or in a combo?....i assume that Mochida has a patent for MND-2119 in Japan...Does Amarin also have to apply for a patent for MND-2119 in the U.S.?
Rose...Generic companies often offer "financial inducements(i.e. bribes) to pharmacy chains to dispense their products in preference to the products of another generic company...This would put Amarin, a company with only ONE generic product at a disadvantage even if their generic Vascepa was superior to other generic"biosimilar" products from larger companies with MULTIPLE generic products to sell.
study..."QUOTE..."Why not settle with Healthnet now when we can still get some type of value especially if we have a generic on the market by second half of this year."
I agree that Amarin needs an authorized generic soon...but but it would advantageous for Amarin to be bought by a BP with a generic arm before marketing a generic Vascepa...rather than than to compete against many generic companies with hundreds of other generic products already on the market...and who have been been making deals with insurance companies to insure that their generic products get sold on a preferred basis.
I believe Denner is the person to manage this sale of Amarin to a BP
Study...Amarin has settled the Healthnet case in a manner that specifically excluded the shareholders from knowing the agreements..Also we have had no information about Amarin's plans for MND-2119 or a FDC in the U.S.
I'm happy that Lisa that Lisa answered your questions, but I wished she had commented on these issues as well.
Thank you, however, for your reporting on your conversation.
Life...Quote..."Does Karim risk embarrassment and let this go to a vote?"
IMO PWO is calling the shots for Amarin in this proxy fight, NOT KM.